LXRX

Lexicon Pharmaceuticals Inc

Sep 17 • 09:37AM ET

1.09

-0.01 -1.36 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN BMRN INCY ALNY IONS NBIX KNSA ALLO

| Held by: VTI VXF SCHA VHT PRFZ QQQS BTEC IBBQ BIB MSSM

Index	-	P/E	-	EPS (ttm)	-0.33	Insider Own	49.76%	Shs Outstand	363.40M	Perf Week	0.46%
Market Cap	394.29M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	0.00%	Shs Float	182.59M	Perf Month	-10.33%
Enterprise Value	316.73M	PEG	-	EPS next Q	-0.07	Inst Own	23.95%	Short Float	15.80%	Perf Quarter	50.57%
Income	-120.62M	P/S	6.75	EPS this Y	69.35%	Inst Trans	-9.78%	Short Ratio	8.84	Perf Half Y	201.81%
Sales	58.43M	P/B	3.05	EPS next Y	-42.11%	ROA	-40.28%	Short Interest	28.84M	Perf YTD	46.92%
Book/sh	0.36	P/C	2.84	EPS next 5Y	31.00%	ROE	-65.30%	52W High	2.17 -50.11%	Perf Year	-35.03%
Cash/sh	0.38	P/FCF	-	EPS past 3/5Y	-1.29% -	ROIC	-63.49%	52W Low	0.28 282.58%	Perf 3Y	-62.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	370.72% -37.35%	Gross Margin	98.14%	Volatility	5.12% 5.46%	Perf 5Y	-32.19%
Dividend TTM	-	EV/Sales	5.42	EPS Y/Y TTM	56.81%	Oper. Margin	-187.35%	ATR (14)	0.06	Perf 10Y	-91.11%
Dividend Ex-Date	-	Quick Ratio	4.16	Sales Y/Y TTM	1504.83%	Profit Margin	-206.43%	RSI (14)	47.25	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	4.16	EPS Q/Q	105.18%	SMA20	-2.93%	Beta	1.20	Target Price	2.75
Payout	-	Debt/Eq	0.47	Sales Q/Q	1652.64%	SMA50	-4.06%	Rel Volume	0.79	Prev Close	1.10
Employees	103	LT Debt/Eq	0.47	Earnings	Aug 06 BMO	SMA200	38.71%	Avg Volume	3.26M	Price	1.09
IPO	Apr 07, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	113.33% 493.04%	Trades		Volume	172,935	Change	-1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2 → $1
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26

Show Previous Ratings

Today 07:00AM	Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings (GlobeNewswire)
Sep-11-25 08:30AM	Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings (GlobeNewswire)
Sep-08-25 08:30AM	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-04-25 08:30AM	Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 (GlobeNewswire)
Sep-03-25 08:30AM	Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 (GlobeNewswire)
08:30AM	Loading…
Sep-02-25 08:30AM	Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress (GlobeNewswire)
Aug-27-25 08:30AM	Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 12:00PM	Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-25 08:45AM	Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates (Zacks) +9.52%
07:47AM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-25 06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks) -6.25%
Jul-31-25 08:00AM	Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-23-25 08:00AM	Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) (Insider Monkey)
08:00AM	Loading…
Jul-18-25 08:00AM	Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) (GlobeNewswire) -8.89%
Jun-23-25 08:00AM	Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-18-25 08:30AM	Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks) -5.91%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +6.93%
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks) +8.46%
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -5.03%
08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
11:44AM	Loading…
May-29-25 11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks) -5.66%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
08:00AM	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%
May-19-25 08:00AM	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology (GlobeNewswire)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
May-14-25 09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance) -15.57%
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
03:18AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.51%
04:06PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 04:30PM	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -8.90%
08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +8.40%
08:00AM	Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 06:10PM	Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) (Seeking Alpha) +64.13% -19.23%
04:17PM	Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1 (Investor's Business Daily)
01:04PM	Novo Nordisk strikes $1bn deal for Lexicons oral obesity drug (Pharmaceutical Technology)
07:30AM	Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 (GlobeNewswire)
Mar-07-25 08:30AM	Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) +6.55%
02:17AM	Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.43%
04:18PM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-25 04:15PM	Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire) +11.00%
Mar-03-25 07:00AM	Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire) -58.17%
Mar-02-25 04:13PM	Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire)
Feb-18-25 08:00AM	Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) (GlobeNewswire)
Jan-21-25 08:00AM	Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +14.25%
Jan-06-25 09:16AM	Heres Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +15.94%
Jan-02-25 08:00AM	Lexicon Appoints Scott Coiante as Chief Financial Officer (GlobeNewswire) +5.23%
Dec-20-24 04:30PM	Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) (GlobeNewswire) +15.71%
Nov-27-24 07:30AM	Lexicon completes subject enrolment for DPNP trial of LX9211 (Clinical Trials Arena)
Nov-26-24 08:00AM	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-25-24 04:15PM	Lexicon Pharmaceuticals to Participate in December Investor Conferences (GlobeNewswire) -5.81%
Nov-22-24 07:32AM	Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA (GlobeNewswire) +11.88%
05:05AM	Lexicon to disband sales team, lay off 60% of staff (BioPharma Dive)
Nov-20-24 04:05PM	Lexicon Appoints Ivan H. Cheung to Board of Directors (GlobeNewswire) -8.34%
Nov-14-24 08:00AM	Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago (GlobeNewswire)
Nov-13-24 02:20AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com) -8.40%
Nov-12-24 05:25PM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.30%
04:25PM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:15AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-07-24 05:02PM	S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate (Investopedia) +7.44%
Nov-06-24 08:00AM	Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference (GlobeNewswire)
02:58AM	A diabetes drug, twice rejected, stumbles again but its developer persists (Pharma Voice)
Nov-05-24 04:05PM	Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
08:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 (GlobeNewswire)
Nov-04-24 08:00AM	Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss (GlobeNewswire)
Oct-31-24 06:54PM	Lexicon Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
Oct-27-24 05:35PM	FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting (TipRanks)
Oct-23-24 09:00AM	New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024 (GlobeNewswire)
Oct-22-24 08:00AM	Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Oct-17-24 07:15AM	Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe (BioPharma Dive) +5.24%
05:55AM	Lexicon partners Viatris for global expansion of sotagliflozin (Pharmaceutical Technology)
Oct-16-24 04:35PM	Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe (GlobeNewswire) +6.70%
04:34PM	Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe (PR Newswire)
Oct-09-24 03:53PM	Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ... (GuruFocus.com)
Sep-27-24 08:00AM	Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress (GlobeNewswire)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Swain Judith L	Director	May 13 '25	Option Exercise	36,810	85,174	May 13 05:52 PM
Sullivan Diane E.	Director	May 13 '25	Option Exercise	36,810	36,810	May 13 05:51 PM
SOBECKI CHRISTOPHER J	Director	May 13 '25	Option Exercise	36,810	203,865	May 13 05:50 PM
BARKER SAM L	Director	May 13 '25	Option Exercise	36,810	124,459	May 13 05:50 PM
Amouyal Philippe	Director	May 13 '25	Option Exercise	36,810	285,174	May 13 05:49 PM
DEBBANE RAYMOND	Director	May 13 '25	Option Exercise	36,810	1,385,689	May 13 05:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXRX

Lexicon Pharmaceuticals Inc

Upgrade your FINVIZ experience